10-K for FY2026, filed Aug 11, 2026
FY2026 revenue by reportable segment ↗$254.2B
10-K for FY2026, filed Aug 11, 2026
$254.2B ↗| Segment | Share | Revenue |
|---|---|---|
|
GMPD
|
5.0%
FY2023: 6.0%
|
GMPD, FY2026
$12.7B Sources
|
|
Other Operating Segment
|
2.7%
FY2023: 2.0%
|
Other Operating Segment, FY2026
$6.8B Sources
|
|
Pharmaceutical and Specialty Solutions
|
92%
FY2023: 92%
|
Pharmaceutical and Specialty Solutions, FY2026
$234.8B Sources
|
Yes. It kept 1 cent of every revenue dollar as net income in FY2026 and turned 2 cents into free cash flow.
10-K for FY2026, filed Aug 11, 2026
$2.6BView ↗
10-K for FY2026, filed Aug 11, 2026
$1.7BView ↗
10-K for FY2026, filed Aug 11, 2026
$4.5BView ↗
Growing. Revenue grew 40% in 4 years, from $181.3B in FY2022 to $254.2B in FY2026, about 9% a year.
Loading...